- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05156502
To Assess Signs and Symptoms in Women Affected by GSM After One Cycle of Pixel CO2-Alma Fractionated Laser
An Open-Label, Interventional, Controlled Study To Assess The Performance And Tolerance Of Pixel CO2-Alma Fractionated Laser in Women Affected by GenitoUrinary Syndrome of Menopause (GSM)
Genitourinary syndrome of menopause (GSM) occurs in approximately 50% of menopausal women but is both underrecognized and undertreated despite numerous treatment options. Vaginal dryness, irritation, dyspareunia, urinary frequency, and urinary urgency are some of the more common symptoms that can have a negative effect on women's lives and relationships. In particular, dyspareunia is localized in the vestibule with specific trophic changes more evident than those localized in vagina. The CO2 fractionated laser, has also been found to be useful in several studies for the treatment of vaginal atrophy.
In this open comparative study, 70 female menopausal subjects aged between 40 and 70 years old at inclusion, having symptoms of GSM (Vaginal dryness, burning/pain, dyspareunia,dysuria), have given her informed consent and meet all the eligibility criteria, will be enrolled. The two groups of comparison will be 35 subjects treated into vagina and vestibule, versus 35 subjects treated into vagina, only. Subjects will come to a total of 6 visits over a period of 3 months.
The primary objective of the study is to evaluate the performance and safety of Pixel CO2-Alma Fractionated Laser comparing its administration into vagina and vestibule versus into vagina, only. The evaluated outcomes are vaginal dryness, burning/pain, dyspareunia, sensitivity to touch at Swab test, Female Sexual Function Index (FSFI) and Vulval Pain Functional Questionnaire (VQ) at day 84 and 120 and the safety during all the study. The secondary objectives are the evaluation of vaginal and vestibular trophism, measured by Vaginal Health Index (VHI) and Vestibular Health Score (VHS) at the FU visits.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Filippo Murina, MD
- Phone Number: +39 0263635420
- Email: filippo.murina@asst-fbf-sacco.it
Study Locations
-
-
-
Milano, Italy, 20154
- Ospedale dei Bambini V Buzzi
-
Contact:
- Filippo Buzzi", MD
- Phone Number: +390263635420
- Email: filippo.murina@asst-fbf-sacco.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- menopausal women aged between 40 and 70 years old (defined as Absence of menstruation for 12 consecutive months).
- women affected by Genitourinary syndrome of menopause (GSM) with Vaginal dryness, burning/pain, dyspareunia, dysuria.
- women not treated with Replacement therapy with estrogen and progestogen (HT) or estrogen alone (ET) or selective estrogen receptor modulators (SERMS) in the last 3 months
Exclusion Criteria:
- hypersensitivity to laser
- clinically significant findings on physical examination
- any chronic medical condition or psychologic disorder that per opinion of the Principal Investigator would make the patient ineligible for the study
- vulvo-vestibular lesion not related with GSM
- active vaginal or vulvar infections (e.g., herpes, candida, STIs)
- prolapse beyond the hymen
- subject has a history of scarring alteration (ie, keloid formation)
- unknown past or active history of vaginal bleeding disorders
- any condition or behavior indicating to the Principal Investigator that the Subject is unlikely to be compliant with study procedures and visits
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Fractionated Laser
|
The Laser will be administered at baseline (visit 2, day 0), at visit 3 (day 28) and at visit 4 (day 56) into vagina and vestibule, following the IFU of the device.
|
ACTIVE_COMPARATOR: Fractionated.Laser
|
Device: Fractionated Laser (Pixel CO2-Alma) The Laser will be administered at baseline (visit 2, day 0), at visit 3 (day 28) and at visit 4 (day 56) into vagina only, following the IFU of the device.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vaginal dryness by Visual Analogue Scale
Time Frame: 120 days
|
The changing will be measured by Visual Analogue Scale (VAS) mean values from baseline to day 84 (visit 5), and 120 (final visit) in each group separately and in the two groups in comparison.
The minimum score is 0 and the maximum score is 10, where 0 represents no symptoms and 10 represents severe symptoms
|
120 days
|
Burning/pain by Visual Analogue Scale
Time Frame: 120 days
|
The changing will be measured by Visual Analogue Scale (VAS) mean values from baseline to day 84 (visit 5), and 120 (final visit) in each group separately and in the two groups in comparison.
The minimum score is 0 and the maximum score is 10, where 0 represents no symptoms and 10 represents severe symptoms
|
120 days
|
Dyspareunia by Visual Analogue Scale
Time Frame: 120 days
|
The changing will be measured by Visual Analogue Scale (VAS) mean values from baseline to day 84 (visit 5), and 120 (final visit) in each group separately and in the two groups in comparison.
The minimum score is 0 and the maximum score is 10, where 0 represents no symptoms and 10 represents severe symptoms
|
120 days
|
Pain/sensitivity to touch at Swab test by Visual Analogue Scale.
Time Frame: 120 days
|
The changing will be measured by Visual Analogue Scale (VAS) mean values from baseline to day 84 (visit 5), and 120 (final visit) in each group separately and in the two groups in comparison.
The minimum score is 0 and the maximum score is 10, where 0 represents no symptoms and 10 represents severe symptoms
|
120 days
|
Sexual Function by Female Sexual Function Index
Time Frame: 120 days
|
Sexual function will be evaluated at baseline and after 84 and 120 days by the Italian validated translation of the Female Sexual Function Index (FSFI), a self-report instrument consisting of 19 items that assess sexual function over the past 4 weeks in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain.
Mean value in each group separately and in the two groups in comparison will be analyzed.
|
120 days
|
Vulval Pain by Vulval Pain Functional Questionnaire
Time Frame: 120 days
|
The Vulval Pain Functional Questionnaire (VQ) will be used to quantify the extent that pelvic pain is affecting the patients.
A numerical value is assigned to each response.
The higher the score the greater the functional limitation.
A diminishing score represents improvement.
|
120 days
|
Incidence of Treatment-Emergent Adverse Events/ Adverse Device Events/ Serious Adverse Events/ Serious Adverse Device Events [Safety and Tolerability]
Time Frame: up to 120 days
|
The incidence will be calculated by searching for Adverse Event (AE), Adverse Device Event ADE, Serious Adverse Event (SAE), Serious Adverse Device Event (SADE) at each visit
|
up to 120 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vestibular Trophism by Vaginal Health Index
Time Frame: 120 days
|
The changing from baseline to day 84 (visit 5) and 120 (final visit) for Vaginal Health Index (VHI) mean value in each group separately and the changing in Arm A in comparison with that occurred in Arm B. The VHI score evaluates 5 parameters (vaginal elasticity, vaginal secretions, vaginal pH, epithelial mucous membrane, vaginal hydration) and to obtain a final score defining the degree of atrophy in the genitourinary tract by assigning a single score to each parameter.
The minim score is 5 and the maxim is 25.
|
120 days
|
Vestibular Trophism by Vestibular Health Score
Time Frame: 120 days
|
Vestibular Health Score (VHS) will be used by the Investigator evaluating 5 parameters (Petechiae, Pallor, Fragility, dryness, Erythema) and to obtain a final score defining the degree of atrophy.
Each item is scored on a Likert scale between 0 =absent and 3 =severe.
Total scores range from 0 to 15.
|
120 days
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SSSM-2020-03.1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
Clinical Trials on Fractionated Laser (Pixel CO2-Alma)
-
Dr. Filippo MurinaOpera CRO, a TIGERMED Group CompanyNot yet recruitingVestibulodynia (VBD) From at Least 6 MonthsItaly
-
Sheba Medical CenterKaplan Medical Center; The Baruch Padeh Medical Center, PoriyaUnknownFemale Stress Urinary Incontinence
-
Alma Lasers Inc.The Cleveland ClinicCompletedAtrophy | Vaginal Atrophy | Genital Diseases, FemaleUnited States
-
Hadassah Medical OrganizationCompletedVaginal Atrophy | Lichen SclerosusIsrael
-
Alma Lasers Inc.CompletedAcne Scars | WrinklesUnited States
-
Icahn School of Medicine at Mount SinaiCompleted
-
Hadassah Medical OrganizationCompletedBreast Cancer | Genitourinary Syndrome of MenopauseIsrael
-
Faculdade de Medicina do ABCCompleted
-
University of MiamiWithdrawnAcne VulgarisUnited States
-
Henry Ford Health SystemCompletedAcne ScarringUnited States